Loading…
Role of Small Dense Low-density Lipoprotein Cholesterol in Cardiovascular Events in Patients with Coronary Artery Disease and Type 2 Diabetes Mellitus Receiving Statin Treatment
Aim: There is little information on the relationships of serum small dense low-density lipoprotein cholesterol (sdLDL-C) levels and serum triglyceride (TG) levels with cardiovascular events in patients with coronary artery disease (CAD) and type 2 diabetes mellitus (DM) who are receiving statins. Th...
Saved in:
Published in: | Journal of Atherosclerosis and Thrombosis 2024/04/01, Vol.31(4), pp.478-500 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c458t-f48c0e76458376f7f20fb4365baad597243a4657d81690c59249e7f7f2921c243 |
container_end_page | 500 |
container_issue | 4 |
container_start_page | 478 |
container_title | Journal of Atherosclerosis and Thrombosis |
container_volume | 31 |
creator | Yamaji, Takayuki Harada, Takahiro Kajikawa, Masato Maruhashi, Tatsuya Kishimoto, Shinji Yusoff, Farina Mohamad Chayama, Kazuaki Goto, Chikara Nakashima, Ayumu Tomiyama, Hirofumi Takase, Bonpei Kohro, Takahide Suzuki, Toru Ishizu, Tomoko Ueda, Shinichiro Yamazaki, Tsutomu Furumoto, Tomoo Kario, Kazuomi Inoue, Teruo Watanabe, Kentaro Takemoto, Yasuhiko Hano, Takuzo Sata, Masataka Ishibashi, Yutaka Node, Koichi Maemura, Koji Ohya, Yusuke Furukawa, Taiji Ito, Hiroshi Yamashina, Akira Koba, Shinji Higashi, Yukihito |
description | Aim: There is little information on the relationships of serum small dense low-density lipoprotein cholesterol (sdLDL-C) levels and serum triglyceride (TG) levels with cardiovascular events in patients with coronary artery disease (CAD) and type 2 diabetes mellitus (DM) who are receiving statins. The aim of this study was to evaluate the relationships of serum TG levels and sdLDL-C levels as residual risks for cardiovascular events in patients with CAD and type 2 DM who were being treated with statins.Methods: The subjects were divided into four groups based on TG levels and sdLDL-C levels: sdLDL-C of <40.0 mg/dL and TG of <150 mg/dL, sdLDL-C of ≥ 40.0 mg/dL and TG of <150 mg/dL, sdLDL-C of <40.0 mg/dL and TG of ≥ 150 mg/dL, and sdLDL-C of ≥ 40.0 mg/dL and TG of ≥ 150 mg/dL. During a median follow-up period of 1419 days, cardiovascular events occurred in 34 patients.Results: The incidences of cardiovascular events were significantly higher in patients with sdLDL-C of ≥ 40.0 mg/dL and TG of <150 mg/dL and in patients with sdLDL-C of ≥ 40.0 mg/dL and TG of ≥ 150 mg/dL, but not in patients with sdLDL-C of <40.0 mg/dL and TG of ≥ 150 mg/dL, than in patients with sdLDL-C of <40.0 mg/dL and TG of <150 mg/dL.Conclusions: Under the condition of treatment with statins, patients with CAD and type 2 DM who had sdLDL-C levels of ≥ 40.0 mg/dL had a high risk for cardiovascular events even though serum TG levels were controlled at <150 mg/dL. |
doi_str_mv | 10.5551/jat.64416 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10999715</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2886598469</sourcerecordid><originalsourceid>FETCH-LOGICAL-c458t-f48c0e76458376f7f20fb4365baad597243a4657d81690c59249e7f7f2921c243</originalsourceid><addsrcrecordid>eNpVUctu1DAUjRCIlsKCH0BewiIliV_xClXT8pAGgdphbd1xbmY8SuJgO1PNZ_GHONMywMY-1-f43GufLHtdFpec8_L9DuKlYKwUT7Lzsq6LnNaSPk2YsoSZrM-yFyHsioJSzqvn2RmVqhK8oufZr1vXIXEtueuh68g1DgHJ0t3nTUI2HsjSjm70LqIdyGKbxCGidx2ZS_CNdXsIZurAk5s9DjHMxHeI9ojvbdyShfNuAH8gVz5dPZBrGxBSFxgasjqMSKp0BGuMGMhX7Dobp0Bu0aDd22FD7mJyG8jKI8Q-ub7MnrXQBXz1uF9kPz7erBaf8-W3T18WV8vcMF7HvGW1KVCKVFApWtlWRbtmVPA1QMOVrBgFJrhs6lKownBVMYVy1qmqNIm9yD48-I7TusfGpNYeOj1626fHaAdW_88Mdqs3bq_LQiklS54c3j46ePdzSh-nextMeiEM6Kagq7oWXNVMqCR99yA13oXgsT31KQs9Z6xTxvqYcdK--Xewk_JPqH8n34UIGzwJwEdrOjxa0VKzeTlanhizBa9xoL8BqeW8oA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2886598469</pqid></control><display><type>article</type><title>Role of Small Dense Low-density Lipoprotein Cholesterol in Cardiovascular Events in Patients with Coronary Artery Disease and Type 2 Diabetes Mellitus Receiving Statin Treatment</title><source>PubMed Central(OA)</source><source>EZB Electronic Journals Library</source><creator>Yamaji, Takayuki ; Harada, Takahiro ; Kajikawa, Masato ; Maruhashi, Tatsuya ; Kishimoto, Shinji ; Yusoff, Farina Mohamad ; Chayama, Kazuaki ; Goto, Chikara ; Nakashima, Ayumu ; Tomiyama, Hirofumi ; Takase, Bonpei ; Kohro, Takahide ; Suzuki, Toru ; Ishizu, Tomoko ; Ueda, Shinichiro ; Yamazaki, Tsutomu ; Furumoto, Tomoo ; Kario, Kazuomi ; Inoue, Teruo ; Watanabe, Kentaro ; Takemoto, Yasuhiko ; Hano, Takuzo ; Sata, Masataka ; Ishibashi, Yutaka ; Node, Koichi ; Maemura, Koji ; Ohya, Yusuke ; Furukawa, Taiji ; Ito, Hiroshi ; Yamashina, Akira ; Koba, Shinji ; Higashi, Yukihito</creator><creatorcontrib>Yamaji, Takayuki ; Harada, Takahiro ; Kajikawa, Masato ; Maruhashi, Tatsuya ; Kishimoto, Shinji ; Yusoff, Farina Mohamad ; Chayama, Kazuaki ; Goto, Chikara ; Nakashima, Ayumu ; Tomiyama, Hirofumi ; Takase, Bonpei ; Kohro, Takahide ; Suzuki, Toru ; Ishizu, Tomoko ; Ueda, Shinichiro ; Yamazaki, Tsutomu ; Furumoto, Tomoo ; Kario, Kazuomi ; Inoue, Teruo ; Watanabe, Kentaro ; Takemoto, Yasuhiko ; Hano, Takuzo ; Sata, Masataka ; Ishibashi, Yutaka ; Node, Koichi ; Maemura, Koji ; Ohya, Yusuke ; Furukawa, Taiji ; Ito, Hiroshi ; Yamashina, Akira ; Koba, Shinji ; Higashi, Yukihito</creatorcontrib><description>Aim: There is little information on the relationships of serum small dense low-density lipoprotein cholesterol (sdLDL-C) levels and serum triglyceride (TG) levels with cardiovascular events in patients with coronary artery disease (CAD) and type 2 diabetes mellitus (DM) who are receiving statins. The aim of this study was to evaluate the relationships of serum TG levels and sdLDL-C levels as residual risks for cardiovascular events in patients with CAD and type 2 DM who were being treated with statins.Methods: The subjects were divided into four groups based on TG levels and sdLDL-C levels: sdLDL-C of <40.0 mg/dL and TG of <150 mg/dL, sdLDL-C of ≥ 40.0 mg/dL and TG of <150 mg/dL, sdLDL-C of <40.0 mg/dL and TG of ≥ 150 mg/dL, and sdLDL-C of ≥ 40.0 mg/dL and TG of ≥ 150 mg/dL. During a median follow-up period of 1419 days, cardiovascular events occurred in 34 patients.Results: The incidences of cardiovascular events were significantly higher in patients with sdLDL-C of ≥ 40.0 mg/dL and TG of <150 mg/dL and in patients with sdLDL-C of ≥ 40.0 mg/dL and TG of ≥ 150 mg/dL, but not in patients with sdLDL-C of <40.0 mg/dL and TG of ≥ 150 mg/dL, than in patients with sdLDL-C of <40.0 mg/dL and TG of <150 mg/dL.Conclusions: Under the condition of treatment with statins, patients with CAD and type 2 DM who had sdLDL-C levels of ≥ 40.0 mg/dL had a high risk for cardiovascular events even though serum TG levels were controlled at <150 mg/dL.</description><identifier>ISSN: 1340-3478</identifier><identifier>EISSN: 1880-3873</identifier><identifier>DOI: 10.5551/jat.64416</identifier><identifier>PMID: 37926523</identifier><language>eng</language><publisher>Japan: Japan Atherosclerosis Society</publisher><subject>Cardiovascular events ; Cholesterol, LDL ; Coronary Artery Disease - drug therapy ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - drug therapy ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Original ; Risk Factors ; Small dense low-density lipoprotein cholesterol ; Statin ; Triglycerides ; Type 2 diabetes mellitus</subject><ispartof>Journal of Atherosclerosis and Thrombosis, 2024/04/01, Vol.31(4), pp.478-500</ispartof><rights>This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.</rights><rights>2024 Japan Atherosclerosis Society 2024</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c458t-f48c0e76458376f7f20fb4365baad597243a4657d81690c59249e7f7f2921c243</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10999715/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10999715/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37926523$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yamaji, Takayuki</creatorcontrib><creatorcontrib>Harada, Takahiro</creatorcontrib><creatorcontrib>Kajikawa, Masato</creatorcontrib><creatorcontrib>Maruhashi, Tatsuya</creatorcontrib><creatorcontrib>Kishimoto, Shinji</creatorcontrib><creatorcontrib>Yusoff, Farina Mohamad</creatorcontrib><creatorcontrib>Chayama, Kazuaki</creatorcontrib><creatorcontrib>Goto, Chikara</creatorcontrib><creatorcontrib>Nakashima, Ayumu</creatorcontrib><creatorcontrib>Tomiyama, Hirofumi</creatorcontrib><creatorcontrib>Takase, Bonpei</creatorcontrib><creatorcontrib>Kohro, Takahide</creatorcontrib><creatorcontrib>Suzuki, Toru</creatorcontrib><creatorcontrib>Ishizu, Tomoko</creatorcontrib><creatorcontrib>Ueda, Shinichiro</creatorcontrib><creatorcontrib>Yamazaki, Tsutomu</creatorcontrib><creatorcontrib>Furumoto, Tomoo</creatorcontrib><creatorcontrib>Kario, Kazuomi</creatorcontrib><creatorcontrib>Inoue, Teruo</creatorcontrib><creatorcontrib>Watanabe, Kentaro</creatorcontrib><creatorcontrib>Takemoto, Yasuhiko</creatorcontrib><creatorcontrib>Hano, Takuzo</creatorcontrib><creatorcontrib>Sata, Masataka</creatorcontrib><creatorcontrib>Ishibashi, Yutaka</creatorcontrib><creatorcontrib>Node, Koichi</creatorcontrib><creatorcontrib>Maemura, Koji</creatorcontrib><creatorcontrib>Ohya, Yusuke</creatorcontrib><creatorcontrib>Furukawa, Taiji</creatorcontrib><creatorcontrib>Ito, Hiroshi</creatorcontrib><creatorcontrib>Yamashina, Akira</creatorcontrib><creatorcontrib>Koba, Shinji</creatorcontrib><creatorcontrib>Higashi, Yukihito</creatorcontrib><title>Role of Small Dense Low-density Lipoprotein Cholesterol in Cardiovascular Events in Patients with Coronary Artery Disease and Type 2 Diabetes Mellitus Receiving Statin Treatment</title><title>Journal of Atherosclerosis and Thrombosis</title><addtitle>JAT</addtitle><description>Aim: There is little information on the relationships of serum small dense low-density lipoprotein cholesterol (sdLDL-C) levels and serum triglyceride (TG) levels with cardiovascular events in patients with coronary artery disease (CAD) and type 2 diabetes mellitus (DM) who are receiving statins. The aim of this study was to evaluate the relationships of serum TG levels and sdLDL-C levels as residual risks for cardiovascular events in patients with CAD and type 2 DM who were being treated with statins.Methods: The subjects were divided into four groups based on TG levels and sdLDL-C levels: sdLDL-C of <40.0 mg/dL and TG of <150 mg/dL, sdLDL-C of ≥ 40.0 mg/dL and TG of <150 mg/dL, sdLDL-C of <40.0 mg/dL and TG of ≥ 150 mg/dL, and sdLDL-C of ≥ 40.0 mg/dL and TG of ≥ 150 mg/dL. During a median follow-up period of 1419 days, cardiovascular events occurred in 34 patients.Results: The incidences of cardiovascular events were significantly higher in patients with sdLDL-C of ≥ 40.0 mg/dL and TG of <150 mg/dL and in patients with sdLDL-C of ≥ 40.0 mg/dL and TG of ≥ 150 mg/dL, but not in patients with sdLDL-C of <40.0 mg/dL and TG of ≥ 150 mg/dL, than in patients with sdLDL-C of <40.0 mg/dL and TG of <150 mg/dL.Conclusions: Under the condition of treatment with statins, patients with CAD and type 2 DM who had sdLDL-C levels of ≥ 40.0 mg/dL had a high risk for cardiovascular events even though serum TG levels were controlled at <150 mg/dL.</description><subject>Cardiovascular events</subject><subject>Cholesterol, LDL</subject><subject>Coronary Artery Disease - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Original</subject><subject>Risk Factors</subject><subject>Small dense low-density lipoprotein cholesterol</subject><subject>Statin</subject><subject>Triglycerides</subject><subject>Type 2 diabetes mellitus</subject><issn>1340-3478</issn><issn>1880-3873</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpVUctu1DAUjRCIlsKCH0BewiIliV_xClXT8pAGgdphbd1xbmY8SuJgO1PNZ_GHONMywMY-1-f43GufLHtdFpec8_L9DuKlYKwUT7Lzsq6LnNaSPk2YsoSZrM-yFyHsioJSzqvn2RmVqhK8oufZr1vXIXEtueuh68g1DgHJ0t3nTUI2HsjSjm70LqIdyGKbxCGidx2ZS_CNdXsIZurAk5s9DjHMxHeI9ojvbdyShfNuAH8gVz5dPZBrGxBSFxgasjqMSKp0BGuMGMhX7Dobp0Bu0aDd22FD7mJyG8jKI8Q-ub7MnrXQBXz1uF9kPz7erBaf8-W3T18WV8vcMF7HvGW1KVCKVFApWtlWRbtmVPA1QMOVrBgFJrhs6lKownBVMYVy1qmqNIm9yD48-I7TusfGpNYeOj1626fHaAdW_88Mdqs3bq_LQiklS54c3j46ePdzSh-nextMeiEM6Kagq7oWXNVMqCR99yA13oXgsT31KQs9Z6xTxvqYcdK--Xewk_JPqH8n34UIGzwJwEdrOjxa0VKzeTlanhizBa9xoL8BqeW8oA</recordid><startdate>20240401</startdate><enddate>20240401</enddate><creator>Yamaji, Takayuki</creator><creator>Harada, Takahiro</creator><creator>Kajikawa, Masato</creator><creator>Maruhashi, Tatsuya</creator><creator>Kishimoto, Shinji</creator><creator>Yusoff, Farina Mohamad</creator><creator>Chayama, Kazuaki</creator><creator>Goto, Chikara</creator><creator>Nakashima, Ayumu</creator><creator>Tomiyama, Hirofumi</creator><creator>Takase, Bonpei</creator><creator>Kohro, Takahide</creator><creator>Suzuki, Toru</creator><creator>Ishizu, Tomoko</creator><creator>Ueda, Shinichiro</creator><creator>Yamazaki, Tsutomu</creator><creator>Furumoto, Tomoo</creator><creator>Kario, Kazuomi</creator><creator>Inoue, Teruo</creator><creator>Watanabe, Kentaro</creator><creator>Takemoto, Yasuhiko</creator><creator>Hano, Takuzo</creator><creator>Sata, Masataka</creator><creator>Ishibashi, Yutaka</creator><creator>Node, Koichi</creator><creator>Maemura, Koji</creator><creator>Ohya, Yusuke</creator><creator>Furukawa, Taiji</creator><creator>Ito, Hiroshi</creator><creator>Yamashina, Akira</creator><creator>Koba, Shinji</creator><creator>Higashi, Yukihito</creator><general>Japan Atherosclerosis Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20240401</creationdate><title>Role of Small Dense Low-density Lipoprotein Cholesterol in Cardiovascular Events in Patients with Coronary Artery Disease and Type 2 Diabetes Mellitus Receiving Statin Treatment</title><author>Yamaji, Takayuki ; Harada, Takahiro ; Kajikawa, Masato ; Maruhashi, Tatsuya ; Kishimoto, Shinji ; Yusoff, Farina Mohamad ; Chayama, Kazuaki ; Goto, Chikara ; Nakashima, Ayumu ; Tomiyama, Hirofumi ; Takase, Bonpei ; Kohro, Takahide ; Suzuki, Toru ; Ishizu, Tomoko ; Ueda, Shinichiro ; Yamazaki, Tsutomu ; Furumoto, Tomoo ; Kario, Kazuomi ; Inoue, Teruo ; Watanabe, Kentaro ; Takemoto, Yasuhiko ; Hano, Takuzo ; Sata, Masataka ; Ishibashi, Yutaka ; Node, Koichi ; Maemura, Koji ; Ohya, Yusuke ; Furukawa, Taiji ; Ito, Hiroshi ; Yamashina, Akira ; Koba, Shinji ; Higashi, Yukihito</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c458t-f48c0e76458376f7f20fb4365baad597243a4657d81690c59249e7f7f2921c243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Cardiovascular events</topic><topic>Cholesterol, LDL</topic><topic>Coronary Artery Disease - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Original</topic><topic>Risk Factors</topic><topic>Small dense low-density lipoprotein cholesterol</topic><topic>Statin</topic><topic>Triglycerides</topic><topic>Type 2 diabetes mellitus</topic><toplevel>online_resources</toplevel><creatorcontrib>Yamaji, Takayuki</creatorcontrib><creatorcontrib>Harada, Takahiro</creatorcontrib><creatorcontrib>Kajikawa, Masato</creatorcontrib><creatorcontrib>Maruhashi, Tatsuya</creatorcontrib><creatorcontrib>Kishimoto, Shinji</creatorcontrib><creatorcontrib>Yusoff, Farina Mohamad</creatorcontrib><creatorcontrib>Chayama, Kazuaki</creatorcontrib><creatorcontrib>Goto, Chikara</creatorcontrib><creatorcontrib>Nakashima, Ayumu</creatorcontrib><creatorcontrib>Tomiyama, Hirofumi</creatorcontrib><creatorcontrib>Takase, Bonpei</creatorcontrib><creatorcontrib>Kohro, Takahide</creatorcontrib><creatorcontrib>Suzuki, Toru</creatorcontrib><creatorcontrib>Ishizu, Tomoko</creatorcontrib><creatorcontrib>Ueda, Shinichiro</creatorcontrib><creatorcontrib>Yamazaki, Tsutomu</creatorcontrib><creatorcontrib>Furumoto, Tomoo</creatorcontrib><creatorcontrib>Kario, Kazuomi</creatorcontrib><creatorcontrib>Inoue, Teruo</creatorcontrib><creatorcontrib>Watanabe, Kentaro</creatorcontrib><creatorcontrib>Takemoto, Yasuhiko</creatorcontrib><creatorcontrib>Hano, Takuzo</creatorcontrib><creatorcontrib>Sata, Masataka</creatorcontrib><creatorcontrib>Ishibashi, Yutaka</creatorcontrib><creatorcontrib>Node, Koichi</creatorcontrib><creatorcontrib>Maemura, Koji</creatorcontrib><creatorcontrib>Ohya, Yusuke</creatorcontrib><creatorcontrib>Furukawa, Taiji</creatorcontrib><creatorcontrib>Ito, Hiroshi</creatorcontrib><creatorcontrib>Yamashina, Akira</creatorcontrib><creatorcontrib>Koba, Shinji</creatorcontrib><creatorcontrib>Higashi, Yukihito</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of Atherosclerosis and Thrombosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yamaji, Takayuki</au><au>Harada, Takahiro</au><au>Kajikawa, Masato</au><au>Maruhashi, Tatsuya</au><au>Kishimoto, Shinji</au><au>Yusoff, Farina Mohamad</au><au>Chayama, Kazuaki</au><au>Goto, Chikara</au><au>Nakashima, Ayumu</au><au>Tomiyama, Hirofumi</au><au>Takase, Bonpei</au><au>Kohro, Takahide</au><au>Suzuki, Toru</au><au>Ishizu, Tomoko</au><au>Ueda, Shinichiro</au><au>Yamazaki, Tsutomu</au><au>Furumoto, Tomoo</au><au>Kario, Kazuomi</au><au>Inoue, Teruo</au><au>Watanabe, Kentaro</au><au>Takemoto, Yasuhiko</au><au>Hano, Takuzo</au><au>Sata, Masataka</au><au>Ishibashi, Yutaka</au><au>Node, Koichi</au><au>Maemura, Koji</au><au>Ohya, Yusuke</au><au>Furukawa, Taiji</au><au>Ito, Hiroshi</au><au>Yamashina, Akira</au><au>Koba, Shinji</au><au>Higashi, Yukihito</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of Small Dense Low-density Lipoprotein Cholesterol in Cardiovascular Events in Patients with Coronary Artery Disease and Type 2 Diabetes Mellitus Receiving Statin Treatment</atitle><jtitle>Journal of Atherosclerosis and Thrombosis</jtitle><addtitle>JAT</addtitle><date>2024-04-01</date><risdate>2024</risdate><volume>31</volume><issue>4</issue><spage>478</spage><epage>500</epage><pages>478-500</pages><artnum>64416</artnum><issn>1340-3478</issn><eissn>1880-3873</eissn><abstract>Aim: There is little information on the relationships of serum small dense low-density lipoprotein cholesterol (sdLDL-C) levels and serum triglyceride (TG) levels with cardiovascular events in patients with coronary artery disease (CAD) and type 2 diabetes mellitus (DM) who are receiving statins. The aim of this study was to evaluate the relationships of serum TG levels and sdLDL-C levels as residual risks for cardiovascular events in patients with CAD and type 2 DM who were being treated with statins.Methods: The subjects were divided into four groups based on TG levels and sdLDL-C levels: sdLDL-C of <40.0 mg/dL and TG of <150 mg/dL, sdLDL-C of ≥ 40.0 mg/dL and TG of <150 mg/dL, sdLDL-C of <40.0 mg/dL and TG of ≥ 150 mg/dL, and sdLDL-C of ≥ 40.0 mg/dL and TG of ≥ 150 mg/dL. During a median follow-up period of 1419 days, cardiovascular events occurred in 34 patients.Results: The incidences of cardiovascular events were significantly higher in patients with sdLDL-C of ≥ 40.0 mg/dL and TG of <150 mg/dL and in patients with sdLDL-C of ≥ 40.0 mg/dL and TG of ≥ 150 mg/dL, but not in patients with sdLDL-C of <40.0 mg/dL and TG of ≥ 150 mg/dL, than in patients with sdLDL-C of <40.0 mg/dL and TG of <150 mg/dL.Conclusions: Under the condition of treatment with statins, patients with CAD and type 2 DM who had sdLDL-C levels of ≥ 40.0 mg/dL had a high risk for cardiovascular events even though serum TG levels were controlled at <150 mg/dL.</abstract><cop>Japan</cop><pub>Japan Atherosclerosis Society</pub><pmid>37926523</pmid><doi>10.5551/jat.64416</doi><tpages>23</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1340-3478 |
ispartof | Journal of Atherosclerosis and Thrombosis, 2024/04/01, Vol.31(4), pp.478-500 |
issn | 1340-3478 1880-3873 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10999715 |
source | PubMed Central(OA); EZB Electronic Journals Library |
subjects | Cardiovascular events Cholesterol, LDL Coronary Artery Disease - drug therapy Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Original Risk Factors Small dense low-density lipoprotein cholesterol Statin Triglycerides Type 2 diabetes mellitus |
title | Role of Small Dense Low-density Lipoprotein Cholesterol in Cardiovascular Events in Patients with Coronary Artery Disease and Type 2 Diabetes Mellitus Receiving Statin Treatment |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T12%3A17%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20Small%20Dense%20Low-density%20Lipoprotein%20Cholesterol%20in%20Cardiovascular%20Events%20in%20Patients%20with%20Coronary%20Artery%20Disease%20and%20Type%202%20Diabetes%20Mellitus%20Receiving%20Statin%20Treatment&rft.jtitle=Journal%20of%20Atherosclerosis%20and%20Thrombosis&rft.au=Yamaji,%20Takayuki&rft.date=2024-04-01&rft.volume=31&rft.issue=4&rft.spage=478&rft.epage=500&rft.pages=478-500&rft.artnum=64416&rft.issn=1340-3478&rft.eissn=1880-3873&rft_id=info:doi/10.5551/jat.64416&rft_dat=%3Cproquest_pubme%3E2886598469%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c458t-f48c0e76458376f7f20fb4365baad597243a4657d81690c59249e7f7f2921c243%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2886598469&rft_id=info:pmid/37926523&rfr_iscdi=true |